Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-31001074 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | JNJ-31001074 10 mg daily for 4 weeks |
| 003 | PLACEBO_COMPARATOR | Placebo one dose daily for 4 weeks |
| 002 | EXPERIMENTAL | JNJ-31001074 30 mg daily for 4 weeks |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | one dose daily for 4 weeks |
| JNJ-31001074 | DRUG | 10 mg daily for 4 weeks |
Inclusion Criteria: * Diagnosis of attention deficit hyperactivity disorder with symptoms from age 7 * In good general health * Willing to not take any other ADHD medication or start any behaviorial modification programs during the study * Willing to use approved birth control throughout the study ...
JNJ-31001074 is an investigational small molecule developed by Johnson & Johnson for Attention Deficit Hyperactivity Disorder (ADHD). It has been studied in pediatric, child, and adult ADHD populations across three completed clinical trials. It is not an approved medicine and remains in clinical development.
JNJ-31001074 was studied as a treatment for Attention Deficit Hyperactivity Disorder. Trials enrolled children aged 6 to 11, pediatric patients aged 12 to 17, and adults aged 18 and older with ADHD. All three studies are completed, and the drug is investigational rather than approved for prescribing.
Johnson & Johnson, which trades under the ticker JNJ, is the developer of JNJ-31001074. The company sponsored the clinical program evaluating the compound in ADHD, including pharmacokinetic, safety, tolerability, and effectiveness studies in children, adolescents, and adults.
JNJ-31001074 has reached Phase 2. The Phase 2 study was a placebo-controlled, randomized, double-blind safety and effectiveness trial in adults with ADHD. Two earlier Phase 1 studies evaluated pharmacokinetics, safety, and tolerability after single-dose administration in children and pediatric patients.
Three completed trials have studied JNJ-31001074: NCT00890292 in pediatric patients aged 12 to 17, NCT00890240 in children aged 6 to 11, and NCT00566449, a Phase 2 safety and effectiveness study in adults with ADHD conducted in the United States. Total enrollment across the program was 68 participants.